Abstract
Background and Objectives The RNAse III DICER is essential for miRNA biogenesis. DICER activity is downregulated in sporadic and genetic forms of ALS. Accordingly, hundreds of miRNAs are broadly downregulated, and their mRNA targets are de-repressed. Enoxacin is a fluoroquinolone, which increases DICER activity and miRNA biogenesis. In an investigator-initiated, first-in-patient phase Ib/IIa study, we tested Enoxacin safety and tolerability in patients with ALS and explored pharmacodynamic biomarkers for Enoxacin target engagement.
Trial design REALS1 was a randomized, double-blind, parallel group study.
Methods Patients with sporadic ALS who met inclusion criteria were dosed with 200mg, 400mg or 600mg oral Enoxacin twice daily for 30 days. Randomization was conducted as per a randomization sequence generated by the study statistician. The study participants, care givers, and those assessing outcomes were blinded to dose assignment throughout the study. The main objective of this trial was safety and tolerability, and primary outcomes were the number and severity of adverse events and number of patients completing dosing. Other objective was pharmacodynamic biomarkers for Enoxacin target engagement, measured by profiling miRNAs by RNA-seq.
Results A total of eight patients were randomized to either 200mg x 2/day (n=3), 400mg x 2/day (n=3) or 600mg x 2/day (n=2). Patients did not experience any serious adverse events. One patient in the 600 mg x 2/day group discontinued the study early, due to adverse events that were not life-threatening. Molecular analysis of cell-free miRNA in plasma and CSF was performed in the 200mg x 2/day and 400mg x 2/day groups, in which all patients completed dosing. This analysis revealed a global increase in plasma and CSF miRNA levels in all post-treatment time points, compared to baseline.
Conclusion Enoxacin is safe and tolerable and provides important evidence for in-patient target engagement. These results encourage testing Enoxacin efficacy in larger trials.
Trial Registration information ClinicalTrials.gov identifier: NCT04840823. Submitted on March 29, 2021. First patient enrolled on April 8, 2021.
Funding ALS Association, ALS Canada, eRARE FP7, Israel Ministry of Health, Muscular Dystrophy Canada, Canadian Institutes of Health Research and Fonds de recherche du Québec - Santé.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04840823
Funding Statement
This study was funded by ALS Association clinical trial award (program: Repurposing Enoxacin therapy for patients with ALS 22 CTA 614), ALS Canada Brain Canada Discovery grant (program: Advanced Pharmacokinetics and Pharmacodynamics for phase Ib/IIa trial of repurposed Enoxacin therapy for patients with ALS), ERA Net for Research Programs on Rare Diseases (eRARE FP7) via the Israel Ministry of Health and Muscular Dystrophy Canada, Canadian Institutes of Health Research (CIHR) and Fonds de recherche du Quebec Sante (FRQS). IM was supported by Teva Pharmaceutical Industries as part of the Israeli National Network of Excellence in Neuroscience (fellowship no. 117941). Research at the Hornstein lab is further funded by Andi and Larry Wolfe Centre for Neuroimmunology and Neuromodulation, the Binational Science Foundation (BSF); Association Francaise Contre les Myopathies (AFM) grants 24882, 28680; Muscular Dystrophy Association (MDA) grant 1280000; Target ALS; Israel Science Foundation (ISF 3497/21, 424/22, 494/24); ALS Canada; Minna James Heineman Stiftung through Minerva, Minerva Foundation, with funding from the Federal German Ministry for Education and Research; Robert Packard Center for ALS Research at Johns Hopkins; McGill University; EU ERA Net; Radala Foundation for ALS Research; Additional support generously provided by the Kekst Family Institute for Medical Genetics. Weizmann SABRA Yeda Sela WRC Program, the Estate of Emile Mimran, and The Maurice and Vivienne Wohl Biology Endowment. Nella and Leon Benoziyo Center for Neurological Diseases. Goldhirsh Yellin Foundation. Dr. Sydney Brenner and friends. Weizmann Center for Research on Neurodegeneration. Redhill Foundation Sam and Jean Rothberg Charitable Trust Dr. Dvora and Haim Teitelbaum Endowment Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Montreal Neurological Institute gave ethical approval for the clinical part of this work. IRB of Weizmann Institute of Science gave athical approval for the molecular part of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We rewrote the abstract and some parts of the manuscript in accordance with CONSORT guidelines for reporting clinical trials
Data Availability
All data produced in the present study are available upon reasonable request to the authors
